1. A pharmaceutical product, characterized in that it consists of β2-microglobulin or a functional variant of this protein, showing at least 70% identity with the human β2-microglobulin protein, in a pharmaceutically acceptable carrier. The pharmaceutical product according to claim 1, wherein said active ingredient is human β2-microglobulin protein. The pharmaceutical product according to claim 1 or 2, wherein said active ingredient is a functional variant of the β2-microglobulin protein exhibiting at least 80% and preferably 90% identity with the human β2-microglobulin protein. The pharmaceutical product of claim 1 for use in the treatment of an autoimmune disease. The pharmaceutical product according to claim 4, characterized in that the autoimmune disease being treated is rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, fibromyalgia, myositis, ankylosing spondylitis, insulin-dependent diabetes mellitus type I, thyroiditis, Hadashim disease, Hashdash’s disease, Hadashim disease, celiac disease, multiple sclerosis, or amyotrophic lateral sclerosis. 6. The pharmaceutical product according to claim 4 for use in the treatment of amyotrophic lateral sclerosis (ALS). The pharmaceutical product according to claim 4 for use in the treatment of multiple sclerosis. The pharmaceutical product according to claim 4 for use in the treatment of Crohn's disease. The pharmaceutical product according to claim 4 for use in the treatment of rheumatoid polyarthritis. The pharmaceutical product according to claim 4 for use in the treatment of insulin-dependent type I diabetes. The pharmaceutical product according to claim 1 for use in pov1. Фармацевтический продукт, отличающийся тем, что он состоит из β2-микроглобулина или функционального варианта этого белка, демонстрирующего по меньшей мере 70% идентичность с человеческим белком β2-микроглобулином, в фармацевтически приемлемом носителе.2. Фармацевтический продукт по п.1, в котором упомянутый активн
